Clinical Trials Directory

Trials / Unknown

UnknownNCT02793661

Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI

Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI (STRENGTH)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
300 (estimated)
Sponsor
European Cardiovascular Research Center · Network
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The Strength study aim to evaluate the use of the RenalGuard device to protect the patients at high risk to develop acute kidney injury following a complex cardiovascular intervention requiring a high volume of contrast.

Detailed description

The Strength Trial is a randomized, international (France and Germany) and multicentre (7) trial. The patients population targeted is suffering from kidney insufficiency (estimated Glomerular Filtration Rate (eGFR) between 15 to 40 ml/min/m2) need to go through a complex cardiovascular intervention.. This is a population of patients at high risk to develop AKI following contrast media administration and complex cardiovascular interventions require a high amount of contrast. Standard treatment is hydration but with risk of hyper and hypohydration for this population of patients. RenalGuard insure the replacement of the urine output by infusion of a matched volume of sterile replacement solution to maintain patients' intravascular fluid volume. The patients are randomized to be protected from contrast-induced nephropathy with the use of RenalGuard or by standard hydration treatment and will be followed-up during 12 months.

Conditions

Interventions

TypeNameDescription
DEVICERenalGuardReplacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
OTHERControlHydration protocol following ESC Guidelines 2014

Timeline

Start date
2016-05-01
Primary completion
2017-05-01
Completion
2018-05-01
First posted
2016-06-08
Last updated
2016-09-05

Locations

7 sites across 2 countries: France, Germany

Source: ClinicalTrials.gov record NCT02793661. Inclusion in this directory is not an endorsement.